rts logo

Nektar Therapeutics (NKTR) Review – Making Smarter Decisions

Nektar Therapeutics (NASDAQ: NKTR) is 84.07% higher on its value in year-to-date trading and has touched a low of $0.41 and a high of $1.12 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The NKTR stock was last observed hovering at around $0.95 in the last trading session, with the day’s gains setting it 0.09%.

Currently trading at $1.04, the stock is 16.58% and 39.40% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.56 million and changing 9.47% at the moment leaves the stock 69.24% off its SMA200. NKTR registered 47.96% gain for a year compared to 6-month gain of 82.49%. The firm has a 50-day simple moving average (SMA 50) of -$0.11 and a 200-day simple moving average (SMA200) of $0.04.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

The stock witnessed a 15.56% loss in the last 1 month and extending the period to 3 months gives it a 74.85%, and is 15.56% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 11.37% over the week and 8.52% over the month.

Nektar Therapeutics (NKTR) has around 137 employees, a market worth around $190.96M and $90.12M in sales. Profit margin for the company is -306.31%. Distance from 52-week low is 152.06% and -7.14% from its 52-week high. The company has generated returns on investments over the last 12 months (-80.69%).

Nektar Therapeutics quarterly earnings per share for the current quarter are estimated at -$0.19 with sales reaching $15.34M over the same period.The EPS is expected to grow by 38.97% this year, but quarterly earnings will post -25.10% year-over-year.

154 institutions hold shares in Nektar Therapeutics (NKTR), with institutional investors hold 67.81% of the company’s shares. The shares outstanding are 191.38M, and float is at 178.15M with Short Float at 1.41%. Institutions hold 67.25% of the Float.

The top institutional shareholder in the company is Deep Track Capital, Lp with over 17.97 million shares valued at $10.34 million. The investor’s holdings represent 9.45% of the NKTR Shares outstanding. As of Jun 29, 2023, the second largest holder is Vanguard Group Inc with 12.06 million shares valued at $6.93 million to account for 6.34% of the shares outstanding. The other top investors are Citadel Advisors Llc which holds 9.7 million shares representing 5.10% and valued at over $5.58 million, while Monaco Asset Management SAM holds 4.87% of the shares totaling 9.26 million with a market value of $5.33 million.

Nektar Therapeutics (NKTR) Insider Activity

The most recent transaction is an insider sale by ROBIN HOWARD W, the company’s President & CEO. SEC filings show that ROBIN HOWARD W sold 20,033 shares of the company’s common stock on Feb 20 ’24 at a price of $0.68 per share for a total of $13622.0. Following the sale, the insider now owns 0.88 million shares.

Nektar Therapeutics disclosed in a document filed with the SEC on Feb 20 ’24 that Zalevsky Jonathan (Chief R&D Officer) sold a total of 9,014 shares of the company’s common stock. The trade occurred on Feb 20 ’24 and was made at $0.68 per share for $6130.0. Following the transaction, the insider now directly holds 0.27 million shares of the NKTR stock.

Still, SEC filings show that on Feb 20 ’24, Wilson Mark Andrew (Chief Legal Officer) disposed off 7,606 shares at an average price of $0.68 for $5172.0. The insider now directly holds 236,674 shares of Nektar Therapeutics (NKTR).

Related Posts